RECRUITING

Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Why Is This Research Study Being Conducted? * The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients. * By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS

Official Title

Defining Inflammatory Biomarkers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes

Quick Facts

Study Start:2024-11-05
Study Completion:2027-11
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06692894

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age ≥18 years
  2. * Histologically confirmed diagnosis of MDS by bone marrow biopsy morphology, using the 2022 World Health Organization (WHO) classification for myeloid neoplasms
  3. * Eastern Cooperative Oncology Group (ECOG) performance status ≤3
  4. * Expected survival of at least 6 months
  5. * Ability to provide consent
  1. * Cases meeting 2022 WHO criteria of MDS with excess blasts 2 as initial diagnosis
  2. * Hematopoietic stem cell transplantation expected within 6 months

Contacts and Locations

Study Contact

Diego Adrianzen Herrera, MD
CONTACT
(802) 656-2021
dadrianz@med.uvm.edu
Neil A Zakai, MD
CONTACT
(802) 656-2021
neil.zakai@med.uvm.edu

Study Locations (Sites)

University of Vermont
Burlington, Vermont, 05495-2038
United States

Collaborators and Investigators

Sponsor: University of Vermont

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11-05
Study Completion Date2027-11

Study Record Updates

Study Start Date2024-11-05
Study Completion Date2027-11

Terms related to this study

Keywords Provided by Researchers

  • Myelodysplastic Syndromes
  • Hematology

Additional Relevant MeSH Terms

  • Myelodysplastic Syndromes, Adult